PFEPfizerRunning, no new patients
TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study A)
Breast Cancer
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 1/2
- Patients
- 37 (final count)
- Started
- Feb 23, 2023
- Main results expected
- Mar 24, 2027
- Fully finished
- Mar 24, 2027
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Phase 1b: number of participants with dose limiting toxicities
Measured over: 28 days
Phase 2: percentage of participants with objective response by investigator assessment
Measured over: Up to approximately 1 year
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT05548127 · record last updated 2026-09-02 · checked 2026-11-09 15:47 UTC